Discover

IONS
Ionis Pharmaceuticals, Inc.
79.19
2 x 72.46
2 x 85.32
bid
ask
-
0.10
0.13%
2 @ 04:00 PM
80.00 +0.81 (1.02%)
Ytd0.10%
1y98.27%
77.95
day range
79.48
39.86
52 week range
86.74
Open79.13Prev Close79.29Low77.95High79.48Mkt Cap13.09B
Vol1.43MAvg Vol1.82MEPS-2.01P/EN/AForward P/E-130.13
Beta0.37Short Ratio10.30Inst. Own107.26%DividendN/ADiv YieldN/A
Ex Div DateN/AEarning08-0550-d Avg75.32200-d Avg75.651yr Est105.91

IONS News

IONS Out-Licenses ex-U.S. Rights for Rare Neurology Drug to Recordati
zacks.com
IONS Out-Licenses ex-U.S. Rights for Rare Neurology Drug to Recordati

Ionis grants Recordati ex-U.S. rights to zilganersen for Alexander disease while retaining U.S. comm

Ionis Pharmaceuticals, Inc. (IONS) Discusses FDA Approval of TRYNGOLZA for Severe Hypertriglyceridemia and Acute Pancreatitis Risk Reduction Transcript
seekingalpha.com
Ionis Pharmaceuticals, Inc. (IONS) Discusses FDA Approval of TRYNGOLZA for Severe Hypertriglyceridem

Ionis Pharmaceuticals, Inc. (IONS) Discusses FDA Approval of TRYNGOLZA for Severe Hypertriglyceridem

FDA Expands IONS' Tryngolza Label to Treat Severe Hypertriglyceridemia
zacks.com
FDA Expands IONS' Tryngolza Label to Treat Severe Hypertriglyceridemia

Ionis wins FDA approval to expand Tryngolza to severe hypertriglyceridemia, opening a broader market

benzinga.com
Goldman Sachs Maintains Neutral on Ionis Pharmaceuticals, Raises Price Target to $75

Goldman Sachs analyst Salveen Richter maintains Ionis Pharmaceuticals (NASDAQ:IONS) with a Neutra

Ionis Climbs As FDA Clears New Therapy To Lower Triglycerides, Pancreatitis Risk
benzinga.com
Ionis Climbs As FDA Clears New Therapy To Lower Triglycerides, Pancreatitis Risk

The U.S. Food and Drug Administration (FDA) approved on Wednesday Ionis Pharmaceuticals, Inc.'s (NAS

Ionis Climbs As FDA Clears New Therapy To Lower Triglycerides, Pancreatitis Risk
benzinga.com
Ionis Climbs As FDA Clears New Therapy To Lower Triglycerides, Pancreatitis Risk

Ionis wins FDA approval for Tryngolza in severe hypertriglyceridemia and signs a Recordati licensing

benzinga.com
Leerink Partners Maintains Outperform on Ionis Pharmaceuticals, Raises Price Target to $129

Leerink Partners analyst Mani Foroohar maintains Ionis Pharmaceuticals (NASDAQ:IONS) with a Outpe

benzinga.com
HC Wainwright & Co. Maintains Buy on Ionis Pharmaceuticals, Raises Price Target to $130

HC Wainwright & Co. analyst Mitchell S. Kapoor maintains Ionis Pharmaceuticals (NASDAQ:IONS)

benzinga.com
Ionis Pharmaceuticals Announces License Agreement With Recordati For Zilganersen In Alexander Diseas

- Recordati brings deep rare disease expertise and proven capabilities in commercialization, access

benzinga.com
Leerink Partners Maintains Outperform on Ionis Pharmaceuticals, Raises Price Target to $122

Leerink Partners analyst Mani Foroohar maintains Ionis Pharmaceuticals (NASDAQ:IONS) with a Outpe

benzinga.com
TD Cowen Reiterates Buy on Ionis Pharmaceuticals, Maintains $108 Price Target

TD Cowen analyst Yaron Werber reiterates Ionis Pharmaceuticals (NASDAQ:IONS) with a Buy and maint

Intellia's One-Time Gene Editing Therapy Gains Ground Against Rivals In Rare Swelling Disorder
benzinga.com
Intellia's One-Time Gene Editing Therapy Gains Ground Against Rivals In Rare Swelling Disorder

Intellia shares rise after new Phase 3 lonvo-z data showed significant reductions in HAE attacks and

benzinga.com
HC Wainwright & Co. Reiterates Buy on Ionis Pharmaceuticals, Maintains $125 Price Target

HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Ionis Pharmaceuticals (NASDAQ:IONS)

benzinga.com
Citigroup Initiates Coverage On Ionis Pharmaceuticals with Buy Rating, Announces Price Target of $11

Citigroup analyst Eric Joseph initiates coverage on Ionis Pharmaceuticals (NASDAQ:IONS) with a Bu

Why Is Biogen Stock Falling Thursday?
benzinga.com
Why Is Biogen Stock Falling Thursday?

Biogen shares slip after mixed Phase 2 Alzheimer's data, but analysts remain optimistic on diran

benzinga.com
Biogen's Topline Data From Phase 2 CELIA Study Of Diranersen (BIIB080) For Early Alzheimer's Disease

Biogen Inc. (NASDAQ:BIIB) today announced compelling topline results from the Phase 2 CELIA study ev

GSK Targets China's Hepatitis B Market Through New Deal
benzinga.com
GSK Targets China's Hepatitis B Market Through New Deal

GSK partnered with Sino Biopharmaceutical to advance hepatitis B drug bepirovirsen in China while la

benzinga.com
RBC Capital Maintains Outperform on Ionis Pharmaceuticals, Raises Price Target to $100

RBC Capital analyst Luca Issi maintains Ionis Pharmaceuticals (NASDAQ:IONS) with a Outperform and

benzinga.com
Barclays Maintains Overweight on Ionis Pharmaceuticals, Raises Price Target to $115

Barclays analyst Eliana Merle maintains Ionis Pharmaceuticals (NASDAQ:IONS) with a Overweight and

benzinga.com
HC Wainwright & Co. Maintains Buy on Ionis Pharmaceuticals, Raises Price Target to $125

HC Wainwright & Co. analyst Mitchell S. Kapoor maintains Ionis Pharmaceuticals (NASDAQ:IONS)

Earnings Scheduled For April 29, 2026
benzinga.com
Earnings Scheduled For April 29, 2026

benzinga.com
Ionis Pharmaceuticals Raises FY2026 Sales Guidance from $800.000M-$825.000M to $875.000M-$900.000M v

Ionis Pharmaceuticals (NASDAQ:IONS) raises FY2026 sales outlook from $800.000 million-$825.000 milli

benzinga.com
Ionis Pharmaceuticals Q1 Adj. EPS $(0.30) Beats $(0.91) Estimate, Sales $246.000M Beat $195.628M Est

Ionis Pharmaceuticals (NASDAQ:IONS) reported quarterly losses of $(0.30) per share which beat the an

benzinga.com
TD Cowen Maintains Buy on Ionis Pharmaceuticals, Lowers Price Target to $108

TD Cowen analyst Yaron Werber maintains Ionis Pharmaceuticals (NASDAQ:IONS) with a Buy and lowers

benzinga.com
Canaccord Genuity Initiates Coverage On Ionis Pharmaceuticals with Buy Rating, Announces Price Targe

Canaccord Genuity analyst Gary Nachman initiates coverage on Ionis Pharmaceuticals (NASDAQ:IONS)

benzinga.com
Morgan Stanley Maintains Overweight on Ionis Pharmaceuticals, Raises Price Target to $130

Morgan Stanley analyst Michael Ulz maintains Ionis Pharmaceuticals (NASDAQ:IONS) with a Overweigh

benzinga.com
Ionis Pharma To Present Additional Results From Pivotal Study Of Zilganersen In Children And Adults

– New data highlight potential treatment benefit across multiple AxD symptom domains, reinforcing zi

Ionis Pharmaceuticals Repriced Drug Ahead Of Key FDA Decision Signals Push Into Larger Market
benzinga.com
Ionis Pharmaceuticals Repriced Drug Ahead Of Key FDA Decision Signals Push Into Larger Market

Ionis Pharmaceuticals cuts Tryngolza price ahead of sHTG decision, with analysts seeing stronger sal

Earnings Scheduled For February 25, 2026
benzinga.com
Earnings Scheduled For February 25, 2026

Cathie Wood Has 13 Big Ideas For 2026: Here's The Ark Invest List And Stocks To Watch
benzinga.com
Cathie Wood Has 13 Big Ideas For 2026: Here's The Ark Invest List And Stocks To Watch

Ark Invest, led by Cathie Wood, issued another "Big Ideas" list on Wednesday, sharing themes

benzinga.com
The Year-End 2025 Biotech Rally And What It Means For 2026

Pharvaris Pill Provides Rapid Relief In Patients With Rare Swelling Attacks, Data Shows
benzinga.com
Pharvaris Pill Provides Rapid Relief In Patients With Rare Swelling Attacks, Data Shows

Pharvaris reports Phase 3 data showing its oral HAE treatment delivers rapid relief, fewer second do

Metagenomi Prioritizes Hemophilia A Program, Lays Off 25% Workforce
benzinga.com
Metagenomi Prioritizes Hemophilia A Program, Lays Off 25% Workforce

Metagenomi reports curative-level FVIII activity for MGX-001 in primates and plans IND filing in 202

benzinga.com
12 Health Care Stocks Moving In Monday's Pre-Market Session

Monday.Com, Metsera, Profrac Holding And Other Big Stocks Moving Lower In Monday's Pre-Market Session
benzinga.com
Monday.Com, Metsera, Profrac Holding And Other Big Stocks Moving Lower In Monday's Pre-Market Sessio

Why Viasat Shares Are Trading Higher By Around 13%; Here Are 20 Stocks Moving Premarket
benzinga.com
Why Viasat Shares Are Trading Higher By Around 13%; Here Are 20 Stocks Moving Premarket

Cathie Wood Goes All-In On Peter Thiel's Crypto Play Bullish With Back-To-Back Million-Dollar Buys
benzinga.com
Cathie Wood Goes All-In On Peter Thiel's Crypto Play Bullish With Back-To-Back Million-Dollar Buys

Cathie Wood-led Ark Invest purchased shares in Bullish, a crypto exchange backed by Peter Thiel, thr

Alphabet To Rally Around 22%? Here Are 10 Top Analyst Forecasts For Thursday
benzinga.com
Alphabet To Rally Around 22%? Here Are 10 Top Analyst Forecasts For Thursday

Earnings Scheduled For October 29, 2025
benzinga.com
Earnings Scheduled For October 29, 2025

This Penumbra Analyst Turns Bullish; Here Are Top 4 Upgrades For Wednesday
benzinga.com
This Penumbra Analyst Turns Bullish; Here Are Top 4 Upgrades For Wednesday

benzinga.com
12 Health Care Stocks Moving In Tuesday's Intraday Session

Air Lease, Ionis Pharmaceuticals, Arrowhead Pharmaceuticals And Other Big Stocks Moving Higher On Tuesday
benzinga.com
Air Lease, Ionis Pharmaceuticals, Arrowhead Pharmaceuticals And Other Big Stocks Moving Higher On Tu

What's Going On With Takeda Stock On Friday?
benzinga.com
What's Going On With Takeda Stock On Friday?

Takeda stock steadies after early dip as FDA clears Ionis' Dawnzera for hereditary angioedema, p

Ionis Pharma Wins FDA Nod For First RNA-Targeted Therapy For Rare Genetic Swelling Disorder
benzinga.com
Ionis Pharma Wins FDA Nod For First RNA-Targeted Therapy For Rare Genetic Swelling Disorder

FDA approved Ionis' Dawnzera for hereditary angioedema, showing up to 87% attack reduction and s

IONS Premarket Gains 2.4% After C-Suite Insider Sells $440K In Stock
benzinga.com
IONS Premarket Gains 2.4% After C-Suite Insider Sells $440K In Stock

Ionis Pharmaceuticals rose 2.38% after hours following a planned stock sale by its chief scientific

benzinga.com
Earnings Scheduled For July 30, 2025

benzinga.com
Earnings Scheduled For April 30, 2025

benzinga.com
Earnings Scheduled For February 19, 2025

Denali Therapeutics' Amyotrophic Lateral Sclerosis Misses Pivotal Trial, But Analyst Says It Was Expected
benzinga.com
Denali Therapeutics' Amyotrophic Lateral Sclerosis Misses Pivotal Trial, But Analyst Says It Was Exp

Denali's DNL343 missed efficacy goals in the HEALEY ALS trial but was well-tolerated. Analysts a

Denali Therapeutics Neurodegenerative Disease Platform Sparks Analyst Optimistic
benzinga.com
Denali Therapeutics Neurodegenerative Disease Platform Sparks Analyst Optimistic

William Blair starts coverage on Denali Therapeutics with an Outperform rating, citing its transport